Socket Graft Injectable

For use when all 4 bony walls are intact after extraction

Socket Graft Injectable is a dual phase calcium phosphate based synthetic bone graft material designed to quickly treat the extraction socket, retain alveolar bone, stimulate bone formation, reduce post-operative complications, and resorb quickly and completely. This product contains no human or animal tissue and carries no potential for allergic or inflammatory reactions.

Socket Graft Injectable is ready to use with no mixing required.

This product is contained in a single-use syringe and should be stored in the refrigerator until use.

Implant placement in 4 weeks, 6 weeks, 12 weeks, or more with predictable results

This biocompatible graft material produces superior bone quality with bone to implant integration due to its osteogenic properties. This material quickly regenerates bone while it completely resorbs and becomes replaced by your patient’s own bone. A faster and healthier bone regeneration sequence allows for an implant to be placed sooner than if other bone grafts were used. Implant placement at 4 weeks, 6 weeks, 12 weeks or more can now be achieved with predictable results.

For the packable version of this graft material, jump to Socket Graft

Socket Graft Injectable

Insurance Codes

D7953 Bone Replacement Graft (Socket Graft)
4267 GTR-Non-Resorbable Membrane

Instructions for Use

  • Remove granulation tissue and any foreign material.
  • Inject the material into the socket beginning at the apex and filling
    toward the gingival margin. Do not mix with any other graft materials other than SteinerBio bone grafts.
  • Using a flat instrument, push the graft material down to completely fill the root structure of the socket. Do not pack the graft material.
  • After condensing and removing excess graft material, cover with a dense PTFE membrane. Do not use animal or human membranes to cover Socket Graft Injectable or the graft may fail.
  • Oral Bond is advised to be placed over the membrane, creating a hermetic seal to prevent oral fluids and bacteria from entering the grafted site.
  • Remove the membrane after 1 month.

Our grafts are categorized by the FDA as both a medical device and a drug. In fact, our bone grafts are the only grafts on the market that the FDA allows to claim that the grafts stimulate osteogenesis.

SteinerBio bone grafts are the only grafts cleared by the FDA for implant placement. If you use any other bone graft cleared by the FDA, they are not approved for implant placement.

All compounds are synthesized ultra-pure, ensuring the process of bone growth is safe, predictable, and effective.

  • No allergic reaction
  • No inflammatory response
  • No human or animal products

Strengthen Your Practice

Socket Graft Injectable will change your practice when your patients realize our technology is available to them. Your patients now have a choice between a chemically pure, FDA cleared bone graft or the frequently off-putting choice of cadaver tissue. Resorbable synthetics and autografts are the only bone grafts that produce normal bone. Normal bone is the only type of bone that has been shown to support an implant for a lifetime.

Socket Graft Injectable provides the organic and inorganic molecules a bone needs to regrow faster, stronger, healthier, and more vital. SteinerBio is the only bone graft company that uses a biologically active compound to physiologically stimulate bone growth, making our products exceptional within regenerative medicine. Our patented SL Factor in our bone graft material targets the osteoblasts within the patient’s bone, initiating the bone regeneration process.

How Does SL Factor Work?

SteinerBio has the only bone grafts on the market that contain a drug that changes the physiology of a bone’s osteoblasts to stimulate osteogenesis. SL Factor, our patented organic compound, enters through the membrane of the osteoblasts and results in the following metabolic activities:

  • SL Factor is absorbed by the osteoblasts
  • SL Factor activates over 300 genes that stimulate the process of bone formation
  • BMP2 and RUNX2 production increases two-fold and reduces osteoclast formation by inhibiting the production of RANK ligand
  • Osteocalcin accumulation is enhanced in the extracellular matrix resulting in excellent mineralization
  • While stored in the osteoblast, SL Factor continues to stimulate bone growth after the synthetic matrix has been resorbed
  • Adipogenesis, osteoclastogenesis, and ODF/RANK ligand expression is inhibited
  • Inflammation is reduced by inhibiting prostaglandin synthesis
“Modern beta tricalcium phosphate bone grafts perform as well or better than allografts or autografts. The negatives of autograft morbidity and cadaver harvesting makes high performing βTCP a superior choice.”


American Society for Bone and Mineral Research (ASBMR)

Tissue Engineering and Regenerative Medicine International Society (TERMIS)

American Academy of Implant Dentistry (AAID)